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).Dear Editor,
We read with interest the letter on our article [1] by Dr. Leong,
and agree on the need for balancing the likelihood of false-
positive versus false-negative cases in the screening scenario [2].
On the other hand, the fact that womenwould accept the likelihood
of false-positive results [3,4] reflects an emotional attitude rather
than a goal of a screening program, in which the recall rate should
be minimized (e.g., <5% according to the European guidelines for
quality assurance in breast cancer screening and diagnosis [5]).
While acknowledging that women’s well being is of paramount
importance, we believe that the above argument should be used
with caution when discussing on the balance between screening
sensitivity and specificity.
We do not agreewith the corresponding colleague on the poten-
tial influence of our results on screening guidelines, since our work
covered a completely different clinical scenario, i.e. the preopera-
tive assessment of breast cancer using contrast-enhancedmagnetic
resonance imaging (CEMRI) versus the combination of unenhanced
magnetic resonance imaging (UMRI) with digital breast tomosyn-
thesis (DBT) (UMRI þ DBT) [1]. In this setting, reducing the false-
positives of preoperative CEMRI is of paramount importance, as
its disappointing specificity is still a matter of debate as a potential
source of surgical overtreatment [6]. We confirm that using
UMRI þ DBT might be helpful at least in decreasing the number
of “second-look” imaging procedures or biopsies prompted by
CEMRI. On the other hand, a reasonably limited increase in small
false-negatives such as the one we observed with UMRI þ DBT
(Tab. 3 and Tab. 4 in the article) is of questionable importance in
the preoperative setting, i.e. in a context in which the index lesion
prompting imaging is already known and has been already bio-
psied.We believe that the observations by Dr. Leong cannot reason-
ably refer to the results of our study.
Finally, we did not propose to extract UMRI images from a full
CEMRI protocol, which would be of questionable significancer Ltd. This is an open access articleonce contrast medium has been administered. Rather, we proposed
performing UMRI only, in line with current research on abbreviated
protocols as a mean to save costs of breast magnetic resonance im-
aging (MRI), and make the examination more rapid and accessible
to patients [1]. Sparse MRI methods proposed by the corresponding
colleague sound interesting as a technical mean to accelerate indi-
vidual MRI sequences. However, regardless of technical character-
istic of each sequence, we need something different, i.e. an MRI
examination balancing fast and safe acquisition with diagnostic ef-
ficacy in a certain clinical scenario.References
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